Prelude Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Prelude Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,053	Closed	-$98K	–	1335
2023 Q1	$98K	Sell	15,053 -1,436	-9%	-$11K	0.01%	953
2022 Q4	$141K	Sell	16,489 -3,205	-16%	-$20.8K	0.01%	1025
2022 Q3	$104K	Sell	19,694 -22,006	-53%	-$108K	﹤0.01%	1162
2022 Q2	$177K	Buy	41,700 +7,700	+23%	+$26.9K	0.01%	1322
2022 Q1	$119K	Buy	34,000 +17,300	+104%	+$75.3K	﹤0.01%	1378
2021 Q4	$111K	Buy	+16,700	New	+$136K	﹤0.01%	1696

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prelude Capital Management's SPRY Position: Q2 2023 in Review

Prelude Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 15,053 shares — an estimated $98K sold.

Prelude Capital Management first reported a position in SPRY in Q4 2021 and held it in 6 quarters. The position peaked at $177K in Q2 2022. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

Prelude Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 15,053 ARS Pharmaceuticals shares in Q2 2023, an estimated $98K.
Prelude Capital Management first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Prelude Capital Management's ARS Pharmaceuticals position peaked at $177K in Q2 2022.
92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.